The role of 18F-FDG PET/CT in distinguishing benign from malignant portal vein thrombosis

Abstract Background Diagnosis of tumour thrombosis and differentiating it from benign are essential for managing patients, planning treatments, minimising unneeded anticoagulation therapy. Bland thrombi occur in both cancer non-cancer patients; bland can coexist. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F - FDG PET/CT) is useful detecting diagnosing distinguishing thrombosis. Objective This study’s aim was to assess the value 18F PET/CT malignant portal vein (PVT) liver cirrhosis patients. Methods A retrospective study conducted on 38 patients who had PVT that histopathologically confirmed performed 18F- scans at our institute between January 2021 April 2022. For all sociodemographic data, visual analysis, semiqualitative analysis (SUV max value), associated hepatic pathology were collected. Results The SUV values significantly higher group (6.26 ± 1.94), compared (1.79 0.69), ( P < 0.001). ROC curve ) revealed a sensitivity 96.3% specificity 36.4%, area under 0.827 with > 3.5 as pathological cut-off distinguish thrombi. Conclusions By using valuable new technique neoplastic PV thrombi, optimal SUVmax criterion.